Research
New Genentech Data for Evrysdi Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with SMA
Genentech, a member of the Roche Group, today announced new interim data from two studies of Evrysdi® (risdiplam)—JEWELFISH and RAINBOWFISH. Genentech leads the clinical development of […]
Read More ›Biogen Presents New Spinraza Data at the 2021 Virtual SMA Conference
Biogen Inc., today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing the strength of […]
Read More ›Cure SMA Publishes Manuscript on SMA Awareness, Screening, and Referral Patterns Amongst Pediatricians
In a May 2021 issue of BMC Pediatrics, Cure SMA published a manuscript, titled “Awareness screening and referral patterns among pediatricians in the United States […]
Read More ›Cure SMA-Funded Researchers at Ohio State University Publish Paper on Effect of Nusinersen in Adults with SMA
Dr. Bakri Elsheikh and colleagues at The Ohio State University have published a paper in the Journal, Frontiers in Neurology, titled “Safety, Tolerability, and Effect of Nusinersen […]
Read More ›Cure SMA-Funded Researchers at Columbia University Publish Paper on Fatigue in SMA
Dr. Jacqueline Montes and colleagues at Columbia University—part of the Pediatric Neuromuscular Clinical Research Network (PNCRN) funded by Cure SMA—have published a paper in the […]
Read More ›Cure SMA Attends Spring 2021 Professional Organization Conferences to Promote Findings from Industry Collaboration Initiatives
Cure SMA is pleased to announce its participation in the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference (March 15-18, 2021) and the […]
Read More ›Genentech Shares New Evrysdi Data on Improved Motor Function and Survival in Babies with SMA Type 1
Genentech, a member of the Roche Group, has shared new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) […]
Read More ›Biogen Shares New Spinraza Data Exploring Opportunities to Improve Outcomes for SMA Patients
Biogen has shared new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with SMA and advancing understanding of the […]
Read More ›Participate in Annual Cure SMA Community Update Survey – Open Now!
Last year presented the us with unique challenges, some we are still managing today. However, it has also reinforced the importance of understanding what the […]
Read More ›Cure SMA Presents Data on Cure SMA Care Center Network and SMA Clinical Data Registry
Cure SMA’s primary focus is supporting care of the highest value to individuals with SMA. As a result of treatments approved by the U.S. Food […]
Read More ›